Auris Medical Holding Ltd. logo
Auris Medical Holding Ltd. EARS

Auris Medical Holding Ltd. Financial Ratios 2011-2026 | EARS

Annual Financial Ratios Auris Medical Holding Ltd.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1.0 -0.6 -0.6 -0.6 -1.2 -4.6 -5.7 - - -

P/S

44.7 - - - - - - - - -

EV/EBITDA

0.5 -0.4 -0.3 -0.5 -0.6 -3.1 -2.5 - - -

PEG

0.04 -0.01 -0.01 -0.02 -0.36 0.12 -0.16 - - -

P/B

0.5 0.7 1.8 -7.3 2.6 3.0 1.9 - - -

P/CF

-1.2 -0.4 -0.5 -0.7 -1.3 -5.0 -5.3 - - -

ROE %

-48.90 -109.87 -315.00 1128.91 -216.80 -66.39 -34.13 - - -

ROA %

-39.43 -71.88 -116.40 -136.93 -85.99 -56.25 -30.57 - - -

ROCE %

-29.73 -104.48 -206.13 -329.18 -113.19 -66.20 -38.82 - - -

DSO

147.2 - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Auris Medical Holding Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 16.45 0.43 % $ 3.92 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.64 -1.89 % $ 1.09 B canadaCanada
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 4.23 % $ 4.53 M chinaChina
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.4 -1.81 % $ 1.39 B britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 76.75 0.85 % $ 1.48 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 19.93 -1.14 % $ 2.51 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.82 -0.14 % $ 8.15 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 66.98 3.8 % $ 12.8 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.88 2.51 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.75 3.79 % $ 11.7 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.24 1.73 % $ 1.16 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.41 4.77 % $ 3.98 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.71 -0.5 % $ 688 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 28.49 0.04 % $ 1.65 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA